Israel - English - Ministry of Health

dexcel pharma technologies ltd - chlorhexidine digluconate - chip - chlorhexidine digluconate 2.5 mg - chlorhexidine - chlorhexidine - the perio- chip is indicated for reduction and/or elimination of pathogenic periodontal pocket microbiota, delaying and/or arresting recolonization of the subgingival microflora, reduction and/or elimination of inflammatory lesions in the periodontal pockets, and as an adjunct to mechanical treatment in periodontitis.

Israel - English - Ministry of Health

dexcel pharma technologies ltd - clopidogrel as besylate - film coated tablets - clopidogrel as besylate 75 mg - clopidogrel - clopidogrel - secondary prevention of atherotrombotic eventsclopidogrel is indicated in:• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome - non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrobmotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.

Israel - English - Ministry of Health

dexcel pharma technologies ltd - valsartan - film coated tablets - valsartan 40 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Israel - English - Ministry of Health

dexcel pharma technologies ltd - valsartan - film coated tablets - valsartan 80 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.for treatment of hypertension.

Israel - English - Ministry of Health

dexcel pharma technologies ltd - valsartan - film coated tablets - valsartan 160 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.for treatment of hypertension.

Israel - English - Ministry of Health

dexcel pharma technologies ltd - losartan potassium - tablets - losartan potassium 12.5 mg - losartan - losartan - heart failure: losardex 12.5 mg is indicated for the treatment of heart failure, when treatment with an ace inhibitor is no longer considered appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex 12.5 mg is not recommended.

Israel - English - Ministry of Health

dexcel pharma technologies ltd - losartan potassium - tablets - losartan potassium 50 mg - losartan - losartan - hypertension: losardex 50 is indicated for the treatment of hypertensionheart failure: losardex 50 is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ace inhibitor is not appropriate.switching patients with heart failure who are stable on an ace inhibitor to losardex 50 is not recommended.renal protection in type-2 diabetic patients with proteinuria: losardex 50 is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex 50 is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy.the benefit of losardex 50 on the primary deposite endpoint was largely driven by reduction in the risk of stroke.

Israel - English - Ministry of Health

dexcel pharma technologies ltd - losartan potassium - tablets - losartan potassium 50 mg - losartan - losartan - hypertension: losardex 50 is indicated for the treatment of hypertensionheart failure: losardex 50 is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ace inhibitor is not appropriate.switching patients with heart failure who are stable on an ace inhibitor to losardex 50 is not recommended.renal protection in type-2 diabetic patients with proteinuria: losardex 50 is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex 50 is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy.the benefit of losardex 50 on the primary deposite endpoint was largely driven by reduction in the risk of stroke.

Israel - English - Ministry of Health

dexcel pharma technologies ltd - losartan potassium - caplets - losartan potassium 100 mg - losartan - losartan - hypertension: losardex 100 is indicated for the treatment of hypertensionheart failure: losardex 100 is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ace inhibitor is not appropriate.switching patients with heart failure who are stable on an ace inhibitor to losardex 100 is not recommended.renal protection in type-2 diabetic patients with proteinuria: losardex 100 is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex 100 is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy.the benefit of losardex 100 on the primary deposite endpoint was largely driven by reduction in the risk of stroke.

Israel - English - Ministry of Health

dexcel pharma technologies ltd - losartan potassium - caplets - losartan potassium 100 mg - losartan - losartan - hypertension: losardex 100 is indicated for the treatment of hypertensionheart failure: losardex 100 is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ace inhibitor is not appropriate.switching patients with heart failure who are stable on an ace inhibitor to losardex 100 is not recommended.renal protection in type-2 diabetic patients with proteinuria: losardex 100 is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex 100 is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy.the benefit of losardex 100 on the primary deposite endpoint was largely driven by reduction in the risk of stroke.